<DOC>
	<DOCNO>NCT00248118</DOCNO>
	<brief_summary>The purpose study determine : 1 ) short-term clinical efficacy safety bupropion help adolescent tobacco smoker quit , 2 ) The role withdrawal symptom maintenance smoking adolescent .</brief_summary>
	<brief_title>Efficacy Safety Bupropion Treatment Adolescent Smoking</brief_title>
	<detailed_description>This 10-week study consist unassisted ( pretrial ) acute tobacco withdrawal ( AW ) phase 7-week randomized double-blind placebo-controlled trial bupropion ( 300 mg/day ) tobacco dependence . Neuropsychological examination conduct baseline , acute withdrawal , treatment ( incl . early withdrawal ) bupropion . We expect smoke cessation approximately 25 % active medication group significant overall smoking reduction . We postulate bupropion also reduce irritability , depress mood anxiety symptom typically occur tobacco withdrawal . We expect observe optimal cognitive performance , ( i.e. , attention , memory ) , affective state satiety , impairment pre-treatment abstinence , intermediate level cognitive performance abstinent active-treatment group . Because limited data available cognitive task adolescent smoker , non-smoking group include order establish validity appropriateness paradigm normative sample .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>More 100 lbs IQ great 80 General good health Not pregnant NonSmoker : No cigarette last 6 month , less 5 lifetime Smokers : Smoke 6 cigarette per day least 6 month Cardiac , Central Nervous System ( CNS ) severe psychiatric disorder Psychoactive medication ( include nicotine replacement ) Substance use disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Placebo-controlled</keyword>
</DOC>